Steel Grove Capital Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-20,978
Closed -$2.35M 184
2025
Q1
$2.35M Sell
20,978
-1,532
-7% -$158K 0.36% 31
2024
Q4
$2.08M Sell
22,510
-2,422
-10% -$218K 0.29% 35
2024
Q3
$2.08M Sell
24,932
-458
-2% -$34.9K 0.29% 39
2024
Q2
$1.74M Buy
25,390
+1,002
+4% +$66.9K 0.24% 55
2024
Q1
$1.79M Sell
24,388
-96
-0.4% -$7.38K 0.24% 65
2023
Q4
$1.98M Sell
24,484
-1,046
-4% -$81.4K 0.27% 47
2023
Q3
$1.91M Sell
25,530
-37
-0.1% -$2.85K 0.26% 55
2023
Q2
$1.97M Buy
25,567
+138
+0.5% +$11K 0.25% 62
2023
Q1
$2.11M Sell
25,429
-4,316
-15% -$357K 0.28% 48
2022
Q4
$2.55M Sell
29,745
-310
-1% -$24.5K 0.36% 36
2022
Q3
$1.85M Buy
30,055
+1,240
+4% +$78.2K 0.33% 41
2022
Q2
$1.78M Buy
28,815
+2,412
+9% +$149K 0.33% 44
2022
Q1
$1.57M Buy
26,403
+1,011
+4% +$64.6K 0.25% 64
2021
Q4
$1.84M Buy
25,392
+1,224
+5% +$84.3K 0.36% 37
2021
Q3
$1.69M Buy
24,168
+287
+1% +$20.2K 0.38% 41
2021
Q2
$1.64M Buy
23,881
+1,679
+8% +$112K 0.45% 46
2021
Q1
$1.44M Buy
+22,202
New +$1.43M 0.47% 50

Other funds holding GILD

Steel Grove Capital Advisors's GILD Position: Q2 2025 in Review

Steel Grove Capital Advisors sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 20,978 shares — an estimated $2.35M sold.

Steel Grove Capital Advisors first reported a position in GILD in Q1 2021 and held it in 17 quarters. The position peaked at $2.55M in Q4 2022. 2,024 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • Steel Grove Capital Advisors reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
  • Steel Grove Capital Advisors sold 20,978 Gilead Sciences shares in Q2 2025, an estimated $2.35M.
  • Steel Grove Capital Advisors first reported a position in Gilead Sciences in Q1 2021 and held it in 17 quarters.
  • Steel Grove Capital Advisors's Gilead Sciences position peaked at $2.55M in Q4 2022.
  • 2,024 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Steel Grove Capital Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.